WealthStone’s Ocular Therapeutix OCUL Stock Holding History

WealthStone’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-10,000	Closed	-$83.3K	–	230
2020 Q2	$83.3K	Buy	+10,000	New	+$66.3K	0.04%	168

Other funds holding OCUL

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WealthStone's OCUL Position: Q3 2020 in Review

WealthStone sold out of Ocular Therapeutix (OCUL) in Q3 2020, closing a stake of 10,000 shares — an estimated $83.3K sold.

WealthStone first reported a position in OCUL in Q2 2020 and held it in 1 quarter. The position peaked at $83.3K in Q2 2020. 108 funds tracked by Wall St. Rank hold OCUL as of Q3 2020.

WealthStone reported no remaining Ocular Therapeutix position as of Q3 2020 after selling out during the quarter.
WealthStone sold 10,000 Ocular Therapeutix shares in Q3 2020, an estimated $83.3K.
WealthStone first reported a position in Ocular Therapeutix in Q2 2020 and held it in 1 quarter.
WealthStone's Ocular Therapeutix position peaked at $83.3K in Q2 2020.
108 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2020.

Based on WealthStone's 13F filing for Q3 2020, filed 9 Nov 2020.